Phillip Pang - 16 Feb 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Chief Medical Officer
Signature
/s/ Howard Horn, Attorney-in-Fact
Issuer symbol
VIR
Transactions as of
16 Feb 2022
Net transactions value
-$246,130
Form type
4
Filing time
18 Feb 2022, 15:47:11 UTC
Previous filing
04 Feb 2022
Next filing
24 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Options Exercise $7,650 +5,000 +5.4% $1.53* 97,777 16 Feb 2022 Direct
transaction VIR Common Stock Sale $157,700 -5,000 -5.1% $31.54 92,777 16 Feb 2022 Direct F1
transaction VIR Common Stock Sale $96,080 -3,009 -3.2% $31.93 89,768 17 Feb 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -5,000 -8.7% $0.000000 52,591 16 Feb 2022 Common Stock 5,000 $1.53 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.
F2 Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F3 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.